Analysts Project Positive Growth for SPDR Portfolio S&P 400 Mid Cap ETF
In our latest analysis at ETF Channel, we examined the SPDR Portfolio S&P 400 Mid Cap ETF (Symbol: SPMD) and its underlying stocks. We compared the trading prices of these stocks with the average 12-month price targets set by analysts. Our findings suggest that the ETF has an implied target price of $60.56 per unit, indicating potential growth.
Potential Upside for SPMD and Key Holdings
Currently priced at approximately $55.27 per unit, SPMD shows a promising upside of 9.57% based on analyst targets for its underlying stocks. Among these holdings, Cytokinetics Inc (Symbol: CYTK), Haemonetics Corp. (Symbol: HAE), and Synaptics Inc (Symbol: SYNA) stand out with significant expected gains. For instance, CYTK is trading at $54.88 per share, with an average target price of $83.06, suggesting a remarkable upside of 51.34%. Similarly, HAE’s recent price of $74.97 highlights a 44.95% increase potential, with analysts targeting $108.67. Additionally, analysts predict SYNA will reach $104.38 per share, marking a 42.59% rise from its current price of $73.20.
Below is a twelve-month price history chart comparing the stock performance of CYTK, HAE, and SYNA:
Summary of Analyst Targets
Here is a table summarizing the current target prices for the mentioned stocks:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| SPDR Portfolio S&P 400 Mid Cap ETF | SPMD | $55.27 | $60.56 | 9.57% |
| Cytokinetics Inc | CYTK | $54.88 | $83.06 | 51.34% |
| Haemonetics Corp. | HAE | $74.97 | $108.67 | 44.95% |
| Synaptics Inc | SYNA | $73.20 | $104.38 | 42.59% |
Assessing Analysts’ Optimism
As we ponder these targets, one must consider whether analysts are justified in their projections or overly optimistic. Historical performance and recent industry developments should be scrutinized to determine if these targets are realistic or outdated. A high price target can indicate confidence in a stock’s potential but may also lead to downgrades if expectations are not met. Investors should conduct further research to form their opinions.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Blue Chip Dividend Stocks Hedge Funds Are Buying
• Institutional Holders of JPMF
• GoDaddy market cap history
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
